CClinicalTrials.gg
CompletedNCT03479255SMARTSTEPUpdated Mar 13, 2025

Smartstep Smartphone PAD

An interventional study of Smartphone-enabled structured exercise therapy (SE-SET) and Standard exercise therapy in Peripheral Arterial Disease, sponsored by Emory University. Completed at 1 site in United States. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2025-03-13.

Sponsored by Emory University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 89 Years
Sex
All
01

Study summary

The study aim is to evaluate the effectiveness of a coached, smartphone-enabled exercise program versus physician directed exercise therapy (usual care).

Read the detailed description

Structured exercise therapy is a first line treatment for symptomatic peripheral artery disease, but compliance is poor. Coaching programs may help but requires significant resources. Smartphone programs may increase the efficiency of such efforts. The study aim is to evaluate the effectiveness of a coached, smartphone-enabled exercise program versus physician directed exercise therapy (usual care) in patients at Grady Memorial Hospital's vascular clinic.

02

Conditions studied

  • Peripheral Arterial Disease

Keywords

  • Smartphone
  • Exercise
  • Functional capacity
03

Who can participate

Ages eligible
18 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Clinically stable intermittent claudication
  • Able to give informed consent
  • Age 18-89 years

And one of the following:

  • ABI \< 0.9 after 10 minutes of rest OR
  • For subjects with an ABI of >1.3 (non-compressible arteries) a Toe-Brachial Index (TBI) of \< 0.70 must be obtained for subject qualification. If ABI is > 0.9 to 1.0, a reduction of 20% in ABI must be measured within 1 minute of treadmill testing.

Exclusion criteria

Exclusion Criteria:

Life-threatening process including:

  • Sepsis
  • Critical limb ischemia (Rutherford class 4-6)
  • Unstable angina
  • Active malignancy with life expectancy \< 6 months
  • Severe NYHA Class IV heart failure

Condition other than PAD that limits walking before claudication onset

This includes, but is not limited to:

  • Severe angina or dyspnea
  • Arthritis
  • Muscle weakness/pain

Active behavioral conditions such as uncontrolled schizophrenia or illicit drug addiction that, in the opinion of the study team, will interfere with active participation

Inability to attend study visits

04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Smartphone-enabled structured exercise therapy (SE-SET)

    This arm involves a smartphone app Movn - rehabilitation platform based on MULTIFIT, a case-management system for secondary prevention and patient surveillance after acute MI. The key features of the smartphone app include daily reminders to exercise, virtual diary for patients to enter data on exercise sessions, two-way secure messaging with the health coach, and educational videos on heart and vascular health.

    Behavioral: Smartphone-enabled structured exercise therapy (SE-SET)

  • Active comparator
    Standard exercise therapy

    Self-directed, unsupervised exercise as prescribed by the patient's physician.

    Behavioral: Standard exercise therapy

Interventions

  • BehavioralSmartphone-enabled structured exercise therapy (SE-SET)

    The SE-SET program lasts a total of 12 weeks per participant. During this time, the application will automatically track physical activity (steps) and subjects will be prompted to enter other health data such as blood pressure and weight and watch brief educational videos on topics such as smoking cessation, low sodium diet, high fruit/vegetable intake, and medication adherence/education. Patients will be contacted by a member of the study team weekly via phone call to identify barriers to patient compliance (issues related to exercise tracking, medication issues that prevent patients from being active, high BP/weight issues) and help patients navigate those barriers. Movn participants can also send direct messages to the study team to ask about non-urgent matters related to their care.

  • BehavioralStandard exercise therapy

    The Standard exercise therapy lasts a total of 12 weeks per participant. Participants will be counseled by the physician to perform exercise at home, including 3 times per week of walking 30+ minutes; if applicable, the physician will also counsel on smoking cessation, low sodium diet, high fruit/vegetable intake, and medication adherence/education. These patients will be given a fitness band, which will be set up by the study team using a de-identified study account that will provide additional data on their progress over time.

05

What researchers measure

Primary outcomes

  1. Change in 6-minute walk test (6MWT) distance completed

    The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.

    Time frame: Immediately before and after the 12-week period

Secondary outcomes

  1. Change in Walking Impairment Questionnaire (WIQ) score

    WIQ measures self-reported walking distance, speed, and stair-climbing ability. In the WIQ distance score, the participant is asked to assess the degree of walking difficulty in walking specific distances on a scale from 0 to 4. A score of 0 represents the inability to walk the distance and a score of 4 represents no difficulty. WIQ speed score assesses the degree of difficulty in walking one block at specific speeds, ranging from walking slowly to jogging, on a scale of 0 to 4. In the WIQ stair-climbing score, the participant is asked to report the degree of difficulty climbing specific numbers of flights of stairs, ranging from one to three flights of stairs, on a scale of 0 to 4. This graded score is multiplied by a prespecified weight for each distance, speed, or number of stair flights. The products are summed and divided by the maximum possible score to obtain a percent score, ranging from 0 (inability to perform any of the tasks) to 100 (representing no difficulty).

    Time frame: Immediately before and after the 12-week period

  2. Change in Physical Health Composite Score of SF-36

    The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. To calculate the scores it is necessary to use special software. The eight sections are: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health.

    Time frame: Immediately before and after the 12-week period

  3. Change in claudication onset time during 6MWT

    One typical symptom of peripheral arterial occlusive disease' (PAOD) is claudication , which is defined as pain, cramps, numbness or a sense of fatigue in the muscles associated with walking, in one or both lower limbs, affecting either the distal or proximal muscle groups.

    Time frame: Immediately before and after the 12-week period

  4. Change in ankle-brachial pressure index (ABPI)

    The ankle-brachial pressure index (ABPI) is the ratio of the blood pressure at the ankle to the blood pressure in the upper arm (brachium). Compared to the arm, lower blood pressure in the leg suggests blocked arteries due to peripheral artery disease (PAD). The ABPI is calculated by dividing the systolic blood pressure at the ankle by the systolic blood pressure in the arm.

    Time frame: Immediately before and after the 12-week period

  5. Change in number of steps/week

    Number of steps/week will be obtained from participants' fitness trackers

    Time frame: Immediately before and after the 12-week period

  6. Critical Limb Ischemia

    Number of Critical Limb Ischemia events reported by participants

    Time frame: Over the 12-week study period

  7. Other Cardiovascular Outcomes

    Number of Cardiovascular Outcomes other than Critical Limb Ischemia events reported by participants

    Time frame: Over the 12-week study period

  8. Exercise-Related Injury

    Number of Exercise-Related Injury events reported by participants

    Time frame: Over the 12-week study period

  9. Mortality

    Number of deaths

    Time frame: Over the 12-week study period

06

Study locations

1 site
  • Grady Health System (non-CRN)
    Atlanta, Georgia 30303, United States
07

Registry details

Key details

Study ID
NCT03479255
Lead sponsor
Emory University
Collaborators
Woodruff Health Sciences Center Foundation
Responsible party
Amit J. Shah (Assistant Professor, Emory University) — Principal investigator
First posted
Mar 27, 2018
Start date
Aug 24, 2018
Primary completion
Feb 20, 2025
Completion
Feb 20, 2025
Last update
Mar 13, 2025

Study contacts

Amit Shah, MD
principal investigator · Emory University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion